OYST News and Press, Oyster Point Pharma Inc. From 05/06/21

PDUFA Target Action Date for OC-01 (varenicline) Nasal Spray is October 17, 2021 Planned U.S. Launch of OC-01 (varenicline) Nasal Spray in Q4 2021, if approved by the FDA OLYMPIA Phase 2 Study on Track, with Planned Enrollment of the First Patient in 1H 2021 Co...

PRINCETON, N.J., May 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, announced today the presentation o...

PRINCETON, N.J., April 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced t...

PRINCETON, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced t...

The FDA has accepted Oyster Point Pharma's (OYST) New Drug Application ((NDA)) for OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease.The PDUFA target action date is October 17.At present, FDA has stated that it does not intend to hold an advisory commi...

Prescription Drug User Fee Act ( PDUFA) target action date is October 17, 2021 U.S. Food and Drug Administration (FDA) has stated that it does not intend to hold an advisory committee meeting to discuss this application Planned U.S. launch of OC-01 (varenicline) nasa...

PRINCETON, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced th...

The following slide deck was published by Oyster Point Pharma, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Oyster Point Pharma, Inc. 2020 Q4 - Results - Earnings Call Presentation

Image source: The Motley Fool. Oyster Point Pharma, Inc. (NASDAQ: OYST) Q4 2020 Earnings Call Feb 18, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Oyster Point Pharma, Inc. (OYST) Q4 2020 Earnings Call Transcript...

Oyster Point Pharma, Inc. (OYST) Q4 2020 Earnings Conference Call February 18, 2021, 04:30 PM ET Company Participants Daniel Lochner - CFO Jeffrey Nau - President and CEO John Snisarenko - Chief Commercial Officer Conference Call Participants Anupam Rama - JPMorgan Tara Bancroft - Piper Sandl...